Citations (114)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (19)
Jianwei Yun, Zhiping Wu, Guoqing Qi, Tiyun Han & Dekui Zhang. (2021) The high-dose amoxicillin-proton pump inhibitor dual therapy in eradication of Helicobacter pylori infection. Expert Review of Gastroenterology & Hepatology 15:2, pages 149-157.
Read now
Read now
P. Unge & A. Berstad. (1996) Pooled Analysis of Anti-Helicobacter pylori Treatment Regimens. Scandinavian Journal of Gastroenterology 31:sup220, pages 27-40.
Read now
Read now
A. A. Ciociola, D. D. Webb & K. Turner. (1996) Dual and Triple Therapy Regimens of Antisecretory Agents and Antibiotics for the Eradication of Helicobacter pylori: An Overview. Scandinavian Journal of Gastroenterology 31:sup218, pages 3-9.
Read now
Read now
P. Unge. (1996) Review of Helicobacter pylori Eradication Regimens. Scandinavian Journal of Gastroenterology 31:sup215, pages 74-81.
Read now
Read now
R. H. Hunt & A. H. Mohamed. (1995) The Current Role of Helicobacter pylori Eradication in Clinical Practice. Scandinavian Journal of Gastroenterology 30:sup208, pages 47-52.
Read now
Read now
J. S. Dixon. (1995) Helicobacter pylori Eradication: Unravelling the Facts. Scandinavian Journal of Gastroenterology 30:sup212, pages 48-62.
Read now
Read now
M. G. Korman & G. N. J. Tytgat. (1995) Helicobacter pylori and Peptic Ulcer. Scandinavian Journal of Gastroenterology 30:sup210, pages 92-96.
Read now
Read now
A. T.R. Axon. (1994) The Role of Acid Inhibition in the Treatment of Helicobacter pylori Infection. Scandinavian Journal of Gastroenterology 29:sup201, pages 16-23.
Read now
Read now
A. T. R. Axon. (1994) The Role of Omeprazole and Antibiotic Combinations in the Eradication of Helicobacter pylori—An Update. Scandinavian Journal of Gastroenterology 29:sup205, pages 31-37.
Read now
Read now
E. Bayerdörffer, G. A. Mannes, A. Sommer, W. Höchter, J. Weingart, R. Hatz, N. Lehn, G. Ruckdeschel, P. Dirschedl & M. Stolte. (1993) Long-Term Follow-up after Eradication of Helicobacter pylori with a Combination of Omeprazole and Amoxycillin. Scandinavian Journal of Gastroenterology 28:sup196, pages 19-25.
Read now
Read now
P. Unge & P. Ekström. (1993) Effects of Combination Therapy with Omeprazole and an Antibiotic on Helicobacter pylori and Duodenal Ulcer Disease. Scandinavian Journal of Gastroenterology 28:sup196, pages 17-18.
Read now
Read now
R. H. Hunt. (1993) Hp and pH: Implications for the Eradication of Helicobacter pylori. Scandinavian Journal of Gastroenterology 28:sup196, pages 12-16.
Read now
Read now
A. T. R. Axon & H. J. O'connor. (1993) Role of Acid Inhibition in the Management of Helicobacter pylori Infection: Chairmen's Introduction. Scandinavian Journal of Gastroenterology 28:sup196, pages 1-2.
Read now
Read now
S. J. Rune, T. Justesen, J. Møller Hansen, T. Gorm Jensen, J. Eriksen, O. Østergaard Thomsen, J. Scheibel, O. Bonnevie, A. Bremmelgaard, M. Vilien, S. Knuhtsen, L. Elsborg, J. Hansen, K. Lauritsen & H. R. Wulff. (1993) Prevention of Duodenal Ulcer Recurrence with Penicillin: A Double-Blind, Placebo-Controlled Trial. Scandinavian Journal of Gastroenterology 28:5, pages 438-442.
Read now
Read now
P. Sherman, B. Shames, V. Loo, A. Matlow, B. Drumm & J. Penner. (1992) Omeprazole Therapy for Helicobacter pylori Infection. Scandinavian Journal of Gastroenterology 27:12, pages 1018-1022.
Read now
Read now
T. U. Westblom, E. Madan, M. A. Subik, D. E. Duriex &B. R. Midkiff. (1992) Double-Blind Randomized Trial of Bismuth Subsalicylate and Clindamycin for Treatment of Helicobacter pylori Infection. Scandinavian Journal of Gastroenterology 27:3, pages 249-252.
Read now
Read now
. (1991) H9. Treatment. Microbial Ecology in Health and Disease 4:sup1, pages S175-S188.
Read now
Read now
E. Dick-Hegedus & A. Lee. (1991) Use of a Mouse Model to Examine Anti-Helicobacter pylori Agents. Scandinavian Journal of Gastroenterology 26:9, pages 909-915.
Read now
Read now
H. Glise. (1990) Epidemiology in Peptic Ulcer Disease : Current Status and Future Aspects. Scandinavian Journal of Gastroenterology 25:sup175, pages 13-18.
Read now
Read now
Articles from other publishers (95)
Jianping Cheng, Chanjuan Fan, Kun Huang, Lili Zhai, Hui Wang, Dongling Xie, Yong Cai, Zhen Li, Qixuan Bai, Pan Wang & Haiou Ding. (2023) Efficacy and safety of high-dose ilaprazole-amoxicillin dual therapy for Helicobacter pylori eradication: a prospective, single-center, randomized trial. Frontiers in Pharmacology 14.
Crossref
Crossref
Chan Hyuk ParkJung Ho ParkYoon Suk Jung. (2023) Comparative Efficacy of Tegoprazan vs Esomeprazole/Sodium Bicarbonate for the Treatment of Helicobacter pylori Infection. Clinical and Translational Gastroenterology 14:11, pages e00632.
Crossref
Crossref
Na‐Yun Su, Qing Shi, Hao Mei, Jie Hu, Yu‐Xiang Liu, Han‐Ning Liu, Heng‐Qi Liu, Yan Guo, Xing‐wei Wang & Chun‐Hui Lan. (2023)
Efficacy and safety of vonoprazan‐based dual therapy and esomeprazole‐based dual therapy in eradicating primary
Helicobacter pylori
infection: A propensity score matching analysis
. Helicobacter.
Crossref
Crossref
Suresh Jain, Sandeep Shamrao Kulkarni, Jyoti R Mahapatra, Dilip Todi, Anup U Petare, Ritwik Banerjee, Rahul Rathod, Syed Naqvi, Amey Mane, Gauri Dhanaki & Bhavesh P Kotak. (2023) Effectiveness of Omeprazole in Acid Peptic Disease: A Real-World, Patient-Reported Outcome Measures Study. Cureus.
Crossref
Crossref
Xin Jiang, Bin Deng, Xuefeng Gao, Yun Zhang, Guangyao Li, Guiqing Li, Qiang She & Yanbing Ding. (2023)
Efficacy analysis of empirical bismuth quadruple therapy, high-dose dual therapy, and resistance gene-based triple therapy as a first-line
Helicobacter pylori
eradication regimen – An open-label, randomized trial
. Open Medicine 18:1.
Crossref
Crossref
Hai-Sheng Qian, Wen-Jie Li, Yi-Ni Dang, Lu-Rong Li, Xiao-Bing Xu, Lin Yuan, Wei-Feng Zhang, Zhen Yang, Xin Gao, Min Zhang, Xuan Li & Guo-Xin Zhang. (2023) Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy. American Journal of Gastroenterology 118:4, pages 627-634.
Crossref
Crossref
Jia‐Lun Guan, Ying‐Ying Han, Mu‐Ru Wang, Su‐Hong Xia, Ji‐Yan Li, Ming‐Yu Zhang, Kai Zhao, Li‐Na Feng, Yu Zhang, Ruo‐Nan Dong, Jia‐Zhi Liao & Pei‐Yuan Li. (2023)
Impact of body size on efficacy of high‐dose dual therapy for
Helicobacter pylori
eradication
. Helicobacter 28:2.
Crossref
Crossref
Wen Gao, Ying Xu, Jianxiang Liu, Xiaolei Wang, Xinhong Dong, Guigen Teng, Binbin Liu, Jinpei Dong, Chaoyi Ge, Hui Ye, Xuezhi Zhang & Hong Cheng. (2023)
A real‐world exploratory study on the feasibility of vonoprazan and tetracycline dual therapy for the treatment of
Helicobacter pylori
infection in special populations with penicillin allergy or failed in previous amoxicillin‐containing therapies
. Helicobacter 28:2.
Crossref
Crossref
Qinyu Yang, Cong He, Yi Hu, Junbo Hong, Zhenhua Zhu, Yong Xie, Xu Shu, Nonghua Lu & Yin Zhu. (2023) 14-day pantoprazole- and amoxicillin-containing high-dose dual therapy for Helicobacter pylori eradication in elderly patients: A prospective, randomized controlled trial. Frontiers in Pharmacology 14.
Crossref
Crossref
Miao DuanJing LiuXiuli Zuo. (2023) Dual therapy for Helicobacter pylori infection. Chinese Medical Journal 136:1, pages 13-23.
Crossref
Crossref
Ben-Gang Zhou, Yu-Zhou Mei, Min Zhang, Xin Jiang, Yao-Yao Li & Yan-Bing Ding. (2023)
High-dose dual therapy
versus
bismuth-containing quadruple therapy for
Helicobacter pylori
eradication: a systematic review and meta-analysis with trial sequential analysis
. Therapeutic Advances in Gastroenterology 16, pages 175628482211477.
Crossref
Crossref
Wen Gao, Guigen Teng, Chi Wang, Ying Xu, Yixuan Li & Hong Cheng. (2022)
Eradication rate and safety of a “simplified rescue therapy”: 14‐day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of
Helicobacter pylori
infection previously failed in eradication: A real‐world, retrospective clinical study in China
. Helicobacter 27:5.
Crossref
Crossref
Jia‐Lun Guan, Yun‐Lian Hu, Ping An, Qiong He, Hui Long, Lin Zhou, Zhi‐Fen Chen, Jian‐Guang Xiong, Shi‐Sheng Wu, Xiang‐Wu Ding, He‐Sheng Luo & Pei‐Yuan Li. (2022)
Comparison of high‐dose dual therapy with bismuth‐containing quadruple therapy in
Helicobacter pylori
‐infected treatment‐naive patients: An open‐label, multicenter, randomized controlled trial
. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 42:3, pages 224-232.
Crossref
Crossref
Chi-Tan Hu. (2022) High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection – A review of the strengths, weaknesses, and proposed solutions. Tzu Chi Medical Journal 34:3, pages 303.
Crossref
Crossref
Zheyu Wang & Fen Wang. (2022)
Efficacy and safety comparison of
Helicobacter pylori
eradication between vonoprazan dual therapy
versus
triple therapy: a systematic review and meta-analysis
. Therapeutic Advances in Gastroenterology 15, pages 175628482211253.
Crossref
Crossref
Hanxin Bi, Xingxing Chen, Yuxin Chen, Xin Zhao, Shasha Wang, Jiehong Wang, Ting Lyu, Shuang Han, Tao Lin, Mingquan Li, Donghong Yuan, Junye Liu & Yongquan Shi. (2022) Efficacy and safety of high-dose esomeprazole–amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial. Chinese Medical Journal 135:14, pages 1707-1715.
Crossref
Crossref
Qiuyue Huang, Zongming Shi, Hong Cheng, Hui Ye & Xuezhi Zhang. (2021) Efficacy and Safety of Modified Dual Therapy as the First-line Regimen for the Treatment of Helicobacter pylori Infection. Journal of Clinical Gastroenterology 55:10, pages 856-864.
Crossref
Crossref
Cailing Li, Yanyan Shi, Baojun Suo, Xueli Tian, Liya Zhou & Zhiqiang Song. (2021)
PPI‐amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the
Helicobacter pylori
eradication therapy within Asia: A systematic review and meta‐analysis
. Helicobacter 26:4.
Crossref
Crossref
Majid T. Moghadam, Zahra Chegini, Amin Norouzi, Amin S. Dousari & Aref Shariati. (2021) Three-Decade Failure to the Eradication of Refractory Helicobacter pylori Infection and Recent Efforts to Eradicate the Infection. Current Pharmaceutical Biotechnology 22:7, pages 945-959.
Crossref
Crossref
Long-Wu Huang & Lei Li. (2021)
Siliankang combined with esomeprazole sodium for treatment of
Helicobacter pylori
-associated gastritis: Efficacy and influence on NF-κB signaling pathway
. World Chinese Journal of Digestology 29:3, pages 131-137.
Crossref
Crossref
Zhiqiang Song, Liya Zhou, Yan Xue, Baojun Suo, Xueli Tian & Zhanyue Niu. (2020)
A comparative study of 14‐day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first‐line
Helicobacter pylori
infection eradication: A randomized trial
. Helicobacter 25:6.
Crossref
Crossref
David Y. Graham. (2020) Transitioning of Helicobacter pylori Therapy from Trial and Error to Antimicrobial Stewardship. Antibiotics 9:10, pages 671.
Crossref
Crossref
Xin-Yi Feng, Yun Zhang & Bin Deng. (2020) Progress in research of high-dose dual therapy as an eradication protocol for Helicobacter pylori infection. World Chinese Journal of Digestology 28:17, pages 847-851.
Crossref
Crossref
Cai‐Ping Gao, Di Zhang, Ting Zhang, Jin‐Xia Wang, Sheng‐Xi Han, David Y. Graham & Hong Lu. (2020)
PPI‐amoxicillin dual therapy for
Helicobacter pylori
infection: An update based on a systematic review and meta‐analysis
. Helicobacter 25:4.
Crossref
Crossref
Yi Zhang, Yang-Jie Zhu, Zhe Zhao, Jing-Tao Zhao, Ting-Yi Wang, Jing Yang, Dong-Feng Chen & Chun-Hui Lan. (2020) Efficacy of modified esomeprazole-amoxicillin dual therapies for Helicobacter pylori infection: an open-label, randomized trial. European Journal of Gastroenterology & Hepatology 32:5, pages 563-568.
Crossref
Crossref
Yang-Jie Zhu, Yi Zhang, Ting-Yi Wang, Jing-Tao Zhao, Zhe Zhao, Jian-Ru Zhu & Chun-Hui Lan. (2020)
High dose PPI-amoxicillin dual therapy for the treatment of
Helicobacter pylori
infection: a systematic review with meta-analysis
. Therapeutic Advances in Gastroenterology 13, pages 175628482093711.
Crossref
Crossref
Lou Yu, Laisheng Luo, Xiaohua Long, Xiao Liang, Yingjie Ji, David Y. Graham & Hong Lu. (2019)
High‐dose PPI‐amoxicillin dual therapy with or without bismuth for first‐line
Helicobacter pylori
therapy: A randomized trial
. Helicobacter, pages e12596.
Crossref
Crossref
Jing Yang, Yi Zhang, Ling Fan, Yang-Jie Zhu, Ting-Yi Wang, Xing-Wei Wang, Dong-Feng Chen & Chun-Hui Lan. (2019) Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori. American Journal of Gastroenterology 114:3, pages 437-445.
Crossref
Crossref
Hiroshi Matsumoto, Akiko Shiotani & David Y. Graham. 2019. Helicobacter pylori in Human Diseases. Helicobacter pylori in Human Diseases
211
225
.
Helge L. Waldum, Per M. Kleveland & Øystein F. Sørdal. (2016)
Helicobacter pylori
and gastric acid: an intimate and reciprocal relationship
. Therapeutic Advances in Gastroenterology 9:6, pages 836-844.
Crossref
Crossref
Maria Pina Dore, Hong Lu & David Y Graham. (2016)
Role of bismuth in improving
Helicobacter pylori
eradication with triple therapy
. Gut 65:5, pages 870-878.
Crossref
Crossref
Taraq A. Attumi & David Y. Graham. (2014)
High-Dose Extended-Release Lansoprazole (Dexlansoprazole) and Amoxicillin Dual Therapy for
H
elicobacter pylori
Infections
. Helicobacter 19:4, pages 319-322.
Crossref
Crossref
Steven L. Percival & David W. Williams. 2014. Microbiology of Waterborne Diseases. Microbiology of Waterborne Diseases
119
154
.
Hala El‐Zimaity & Robert H. Riddell. 2013. Morson and Dawson's Gastrointestinal Pathology. Morson and Dawson's Gastrointestinal Pathology
110
161
.
Charles E. Copeland & Kurt Stahlfeld. (2012) Two Tall Poppies and the Discovery of Helicobacter Pylori. Journal of the American College of Surgeons 214:2, pages 237-241.
Crossref
Crossref
Paul Moayyedi, Shelly Soo, Jonathan J Deeks, Brendan Delaney, Adam Harris, Michael Innes, R Oakes, Sue Wilson, A Roalfe, Cathy Bennett & David Forman. (2011) Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database of Systematic Reviews.
Crossref
Crossref
David Y. Graham, Syed Ussama Javed, Sara Keihanian, Suhaib Abudayyeh & Antone R. Opekun. (2010) Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States. Journal of Gastroenterology 45:8, pages 816-820.
Crossref
Crossref
Hala El-Zimaity. (2009) Corpus predominant gastritis: what does it mean?. Current Opinion in Gastroenterology 25:6, pages 566-569.
Crossref
Crossref
Lisa J. Murray, Melissa Gabello, David S. Rudolph, Christopher P. Farrell, Melissa Morgan, Aaron P. Martin, James C. Underwood, M. Carmen Valenzano & James M. Mullin. (2008) Transmucosal Gastric Leak Induced by Proton Pump Inhibitors. Digestive Diseases and Sciences 54:7, pages 1408-1417.
Crossref
Crossref
David Y. Graham & Robert M. Genta. (2008) Long-term proton pump inhibitor use and gastrointestinal cancer. Current Gastroenterology Reports 10:6, pages 543-547.
Crossref
Crossref
Javier P. Gisbert, Ramón Pajares & José María Pajares. (2007) Evolution of Helicobacter pylori Therapy from a Meta-analytical Perspective. Helicobacter 12:s2, pages 50-58.
Crossref
Crossref
Javier P. Gisbert, Carlos Esteban, Isabel Jimenez & Ricardo Moreno-Otero. (2007)
13
C-urea Breath Test during Hospitalization for the Diagnosis of Helicobacter pylori Infection in Peptic Ulcer Bleeding
. Helicobacter 12:3, pages 231-237.
Crossref
Crossref
Brian J. Egan & Colm A. O'Morain. (2007) A historical perspective of Helicobacter gastroduodenitis and its complications. Best Practice & Research Clinical Gastroenterology 21:2, pages 335-346.
Crossref
Crossref
Paul Moayyedi, Shelly Soo, Jonathan J Deeks, Brendan Delaney, Adam Harris, Michael Innes, R Oakes, Sue Wilson, A Roalfe, Cathy Bennett & David Forman. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
J.P. Gisbert & J.M. Pajares. (2005) 13C-urea breath test in the management of Helicobacter pylori infection. Digestive and Liver Disease 37:12, pages 899-906.
Crossref
Crossref
P Moayyedi, S Soo, J Deeks, B Delaney, A Harris, M Innes, R Oakes, S Wilson, A Roalfe, C Bennett & D Forman. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Steven Percival, Rachel Chalmers, Martha Embrey, Paul Hunter, Jane Sellwood & Peter Wyn-Jones. 2004. Microbiology of Waterborne Diseases. Microbiology of Waterborne Diseases
91
123
.
Carlos Martín de Argila & Daniel Boixeda. (2001) Consideraciones prácticas para el diagnóstico de la infección por Helicobacter pylori. Medicina Clínica 117:10, pages 386-391.
Crossref
Crossref
H. Kagaya, M. Kato, Y. Komatsu, T. Mizushima, M. Sukegawa, K. Nishikawa, K. Hokari, H. Takeda, T. Sugiyama & M. Asaka. (2001)
High‐dose ecabet sodium improves the eradication rate of
Helicobacter pylori
in dual therapy with lansoprazole and amoxicillin
. Alimentary Pharmacology & Therapeutics 14:11, pages 1523-1527.
Crossref
Crossref
Peter Malfertheiner, Andreas Leodolter & Ulrich Peitz. (2000) Cure of Helicobacter pylori -associated ulcer disease through eradication. Best Practice & Research Clinical Gastroenterology 14:1, pages 119-132.
Crossref
Crossref
Alain Lozniewski, Adrien Duprez, Corinne Renault, Filipe Muhale, Marie-Christine Conroy, Michele Weber, Alain Le Faou & Francois Jehl. (1999)
Gastric Penetration of Amoxicillin in a Human
Helicobacter pylori
-Infected Xenograft Model
. Antimicrobial Agents and Chemotherapy 43:8, pages 1909-1913.
Crossref
Crossref
Tore Lind, Francis Mégraud, Peter Unge, Ekkehard Bayerdörffer, Colm O'Morain, Robin Spiller, Sander Veldhuyzen van Zanten, Karna Dev Bardhan, Magnus Hellblom, Michael Wrangstadh, Lars Zeijlon & Christer Cederberg. (1999) The MACH2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 116:2, pages 248-253.
Crossref
Crossref
B. D. Gold. 1999. Gastroduodenal Disease and Helicobacter pylori. Gastroduodenal Disease and Helicobacter pylori
71
102
.
P. Unge. 1999. Gastroduodenal Disease and Helicobacter pylori. Gastroduodenal Disease and Helicobacter pylori
261
300
.
Peter Malfertheiner. 1999. Proton Pump Inhibitors. Proton Pump Inhibitors
173
191
.
Ohkusa, Takashimizu, Fujiki, Araki, Ariake, Shimoi, Honda, Enomoto, Sakurazawa, Horiuchi, Suzuki, Ishii & Ishikura. (1998) Prospective evaluation of a new anti-ulcer agent, ecabet sodium, for the treatment of Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics 12:5, pages 457-461.
Crossref
Crossref
A Lozniewski, J.D de Korwin, F Muhale & F Jehl. (1998) Gastric diffusion of antibiotics used against Helicobacter pylori. International Journal of Antimicrobial Agents 9:3, pages 181-193.
Crossref
Crossref
Peter Unge. (1997) What Other Regimens Are Under Investigation to Treat Helicobacter pylori Infection?. Gastroenterology 113:6, pages S131-S148.
Crossref
Crossref
J. Labenz, J.A. Beker, C.P.M. Dekkers, A. Farley, H.‐U. Klör & A. Jönsson. (2003)
Doubling the omeprazole dose (40 mg b.d. vs. 20 mg b.d.) in dual therapy with amoxycillin increases the cure rate of
Helicobacter pylori
infection in duodenal ulcer patients
. Alimentary Pharmacology & Therapeutics 11:3, pages 515-522.
Crossref
Crossref
Tore Lind, Sander Veldhuyzen van Zanten, Peter Unge, Robin Spiller, Ekkehard Bayerdörffer, Colm O'Morain, Karna Dev Bardhan, Marc Bradette, Naoki Chiba, Michael Wrangstadh, Christer Cederberg & Jan‐Peter Idström. (2007) Eradication of Helicobacter pylori Using One‐week Triple Therapies Combining Omeprazole with Two Antimicrobials: The MACH I Study. Helicobacter 1:3, pages 138-144.
Crossref
Crossref
J E SjöströmJ FryklundT KühlerH Larsson. (1996) In vitro antibacterial activity of omeprazole and its selectivity for Helicobacter spp. are dependent on incubation conditions. Antimicrobial Agents and Chemotherapy 40:3, pages 621-626.
Crossref
Crossref
Yoram Bujanover, Shimon Reif & Jacob Yahav. (1996) HELICOBACTER PYLORI AND PEPTIC DISEASE IN THE PEDIATRIC PATIENT. Pediatric Clinics of North America 43:1, pages 213-234.
Crossref
Crossref
K. E. L. McColl. (1996) Helicobacter pylori infection and its role in human disease ? an overview. Pharmacy World and Science 18:2, pages 49-55.
Crossref
Crossref
John CalamJohn Calam. 1996. Clinicians’ Guide to Helicobacter pylori. Clinicians’ Guide to Helicobacter pylori
1
21
.
G. D. BELL, C. M. BATE, A. T. R. AXON, G. TILDESLEY, G. D. KERR, J. R. B. GREEN, C. E. EMMAS & M. D. TAYLOR. (2007) Addition of metronidazole to omeprazole/amoxycillin dual therapy increases the rate of Helicobacter pylori eradication: a double‐blind, randomized trial. Alimentary Pharmacology & Therapeutics 9:5, pages 513-520.
Crossref
Crossref
Ekkehard Bayerdörffer, Stephan Miehlke, Gerd A. Mannes, Albrecht Sommer, Wilhelm Höchter, Josef Weingart, Walter Heldwein, Hermann Klann, Thomas Simon, Wolfgang Schmitt, Elke Bästlein, Albert Eimiller, Rudolf Hatz, Norbert Lehn, Peter Dirschedl & Manfred Stolte. (1995) Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 108:5, pages 1412-1417.
Crossref
Crossref
JOSEPH J. Y. SUNG, S. C. SYDNEY CHUNG, SHORLAND W. HOSKING, RAPHAEL C. Y. CHAN, THOMAS K. W. LING, MAN‐YEE YUNG, AUGUSTINE F. B. CHENG & ARTHUR K. C. LI. (2008)
Mucosal pharmacokinetics and pilot study of short course of parenteral imipenem in the eradication of
Helicobacter pylori
. Journal of Gastroenterology and Hepatology 10:1, pages 66-69.
Crossref
Crossref
Neville D. Yeomans, Roger W. Brimblecombe, James Elder, Richard V. Heatley, J. J. Misiewicz, Timothy C. Northfield & Anthony Pottage. (1995) Effects of acid suppression on microbial flora of upper gut. Digestive Diseases and Sciences 40:S2, pages 81S-95S.
Crossref
Crossref
Zhongming Ge, Koji Hiratsuka & Diane E. Taylor. (2006)
Nucleotide sequence and mutational analysis indicate that two
Helicobacter pylori
genes encode a P‐type ATPase and a cation‐binding protein associated with copper transport
. Molecular Microbiology 15:1, pages 97-106.
Crossref
Crossref
A. Burette & Y. Glupczynski. (1995) Helicobacter pylori: The place of the new macrolides in the eardication of the bacteria in peptic ulcer disease. Infection 23:S1, pages S44-S52.
Crossref
Crossref
J. G. PENSTON. (2007) Review article: Helicobacter pylori eradication–understandable caution but no excuse for inertia. Alimentary Pharmacology & Therapeutics 8:4, pages 369-389.
Crossref
Crossref
G. N. J. TYTGAT. (2007) Review article: treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence. Alimentary Pharmacology & Therapeutics 8:4, pages 359-368.
Crossref
Crossref
M. T. AL‐ASSI, R. M. GENTA & D. Y. GRAHAM. (2007) Short Report: omeprazole‐tetracycline combinations are inadequate as therapy for Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics 8:2, pages 259-262.
Crossref
Crossref
R. H. Hunt. 1994. Helicobacter pylori. Helicobacter pylori
584
592
.
G. N. J. Tytgat & L. A. Noach. 1994. Helicobacter pylori. Helicobacter pylori
550
569
.
M. Deltenre, E. De Koster & J. F. Nyst. 1994. Basic and Clinical Aspects of Helicobacter pylori Infection. Basic and Clinical Aspects of Helicobacter pylori Infection
251
257
.
Y. Glupczynski. (1993) In vitro susceptibility testing of Helicobacter pylori to antimicrobial Agents: Basis for treatment or microbiologists' obsession?. Zentralblatt für Bakteriologie 280:1-2, pages 227-238.
Crossref
Crossref
Antonio Tucci, Roberto Corinaldesi, Vincenzo Stanghellini, Giovanni F. Paparo, Stefano Gasperoni, Guido Biasco, Ornella Varoli, Marco Ricci-Maccarini & Luigi Barbara. (1993) One-day therapy for treatment ofHelicobacter pylori infection. Digestive Diseases and Sciences 38:9, pages 1670-1673.
Crossref
Crossref
C. J. McCARTHY, R. COLLINS, S. BEATTIE, H. HAMILTON & C. O'MORAIN. (2007) Short report: treatment of Helicobacter pylori‐associated duodenal ulcer with omeprazole plus antibiotics. Alimentary Pharmacology & Therapeutics 7:4, pages 463-466.
Crossref
Crossref
J. W. FRESTON. (2007) Future prospects for proton pump inhibitors. Alimentary Pharmacology & Therapeutics 7, pages 68-75.
Crossref
Crossref
Barry J. Marshall. (1993) TREATMENT STRATEGIES FOR HELICOBACTER PYLORI INFECTION. Gastroenterology Clinics of North America 22:1, pages 183-198.
Crossref
Crossref
G.N.J. Tytgat, L.A. Noach & E.A.J. Rauws. (1993) HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE. Gastroenterology Clinics of North America 22:1, pages 127-139.
Crossref
Crossref
D. Y. GRAHAM, G. M. LEW, F. C. RAMIREZ, R. M. GENTA, P. D. KLEIN & H. M. MALATY. (2007) Short report: a non‐metronidazole triple therapy for eradication of Helicobacter pylori infection–tetracycline, amoxicillin, bismuth. Alimentary Pharmacology & Therapeutics 7:1, pages 111-114.
Crossref
Crossref
Tony Axon. 1993. Helicobacter pylori Infection. Helicobacter pylori Infection
149
157
.
V. Lamy, B. Ramdani, A. Floriani, D. Famerée, J. Cappelli & R. Moisse. 1993. Helicobacter pylori and Gastroduodenal Pathology. Helicobacter pylori and Gastroduodenal Pathology
352
354
.
G. D. BELL, K. U. POWELL, S. M. BURRIDGE, G. SPENCER, G. BOLTON, K. PURSER, S. BROOKS, S. PROSSER, G. HARRISON, P. W. GANT, P. H. JONES & J. E. TROWELL. (2007) Short report: omepmzole plus antibiotic combinations for the eradication of metronidazole-resistant Helicobacter pylori. Alimentary Pharmacology & Therapeutics 6:6, pages 751-758.
Crossref
Crossref
David Y Graham, Juan Colon-Pagan, Richard S Morse, Thomas L Johnson, John H Walsh, Arthur J McCullough, Jay W Marks, Manuel Sklar, Richard C Stone, Angeline J Cagliola, Karen L Walton-Bowen & Thomas J Humphries. (1992) Ulcer recurrence following duodenal ulcer healing with omeprazole, ranitidine, or placebo: A double-blind, multicenter, 6-month study. Gastroenterology 102:4, pages 1289-1294.
Crossref
Crossref
H. Rautelin, M. Vaara, O. V. Renkonen, T. U. Kosunen & K. Seppälä. (1992) In vitro activity of antifungal azoles againstHelicobacter pylori. European Journal of Clinical Microbiology & Infectious Diseases 11:3, pages 273-274.
Crossref
Crossref
J. WEIL, G. D. BELL, K. POWELL, A. MORDEN, G. HARRISON, P. W. GANT, P. H. JONES & J. E. TROWELL. (2007)
Omeprazole and
Helicobacter Pylori
: temporary suppression rather than true eradication
. Alimentary Pharmacology & Therapeutics 5:3, pages 309-313.
Crossref
Crossref
Francis Megraud, Ludmila Boyanova & Herve Lamouliatte. (1991) Activity of lansoprazole against Helicobacter pylori. The Lancet 337:8755, pages 1486.
Crossref
Crossref
E.A.J. Rauws, W. Langenberg, A. Bosma, J. Dankert & G.N.J. Tytgat. (1991) Lack of eradication of Helicobacter pylori after omeprazole. The Lancet 337:8749, pages 1093.
Crossref
Crossref
W. M. Hui, S. K. Lam, J. Ho, C. L. Lai, A. S. F. Lok, M. M. T. Ng, W. Y. Lau & F. J. Branicki. (1991) Effect of omeprazole on duodenal ulcer-associated antral gastritis andHelicobacter pylori. Digestive Diseases and Sciences 36:5, pages 577-582.
Crossref
Crossref
S. Suerbaum, H. Leying, K. Klemm & W. Opferkuch. (1991) Antibacterial activity of pantoprazole and omeprazole againstHelicobacter pylori. European Journal of Clinical Microbiology & Infectious Diseases 10:2, pages 92-93.
Crossref
Crossref
T. Ulf Westblom & Dennis E. Duriex. (1991) Enhancement of antibiotic concentrations in gastric mucosa by H2-receptor antagonist. Digestive Diseases and Sciences 36:1, pages 25-28.
Crossref
Crossref
Amar Bhide, Srikant Datar & Katherine Stebbins. (2019) Case Histories of Significant Medical Advances: Eradicating Helicobacter Pylori Infections to Treat Ulcers. SSRN Electronic Journal.
Crossref
Crossref